Ann: Encouraging Phase II TACTI-002 data reported at SITC 2020, page-37

Conclusions

As checkpoint immunotherapies targeting inhibitory coreceptors PD-1 and CTLA-4 revolutionized cancer treatment, LAG-3 is expected to be a highly promising target in cancer therapies. However, our understanding of LAG-3 is still very limited and many fundamental questions remain unanswered. The signaling mechanism of LAG-3 is unknown and the ligands of LAG-3 are perplexing. LAG-3 is expressed on a variety of cell types. However, the function of LAG-3 and the effect of LAG-3 blockade in each type of cells have not been elucidated. We also need to examine the functional differences, redundancies, and co-operations of LAG-3 and other coreceptors. By elucidating the functional properties of LAG-3 more in detail, we can rationally design LAG-3-targeted therapies for various diseases, such as cancer, autoimmunity, and infection.


The things these conclusions have highlighted are part of Immuteps collaboration with
the Monash Uni under Prof Jamie Rossjohn...They are basically trying to find an understanding
of the above..

I'm sure tuts can refine my comments but that's about all I am capable off...